SCYX — SCYNEXIS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1178253 ·
Last close
$4.22
Market Cap
$41.99M
52W High
$9.12
52W Low
$3.53
ADV30
385,703
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 235,000 | — | -7,775,000 | 7,397,000 | 74,970,000 | 10,487,000 | 8,040,000 |
| Mar 2026 | 0 | — | -16,939,000 | -21,299,000 | 77,626,000 | 36,671,000 | 36,319,000 |
| Dec 2025 | 18,646,000 | — | 10,521,000 | 12,258,000 | 59,027,000 | 21,259,000 | 9,651,000 |
| Sep 2025 | 334,000 | — | -8,405,000 | -8,591,000 | 51,071,000 | 14,797,000 | 14,641,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,919,000
Investing CF
$11,341,000
Financing CF
$23,952,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.72
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-406,443,000
Inventory
—
Receivables
$0
ST Investments
$22,592,000
EBIT TTM
$-24,517,000
Pretax Income TTM
$-24,517,000
Interest Exp TTM
$0
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$19,216,000
EBITDA
—
Free Cash Flow
$-7,323,375
Enterprise Value
$-3,981,892
Total Cash
$54,083,000
Total Debt
$1,945,000
Shares Out
9,949,609
Trailing EPS
$-0.91
Book Value
$6.73
ROE
-18.4%
ROA
-20.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 20,601,000 | -16,074,000 | -8,609,000 | 59,027,000 | 9,651,000 | 49,376,000 | -5,283,000 |
| Dec 2024 | 3,746,000 | -37,117,000 | -21,288,000 | 90,643,000 | 35,566,000 | 55,077,000 | -24,009,000 |
| Dec 2023 | 140,141,000 | 72,669,000 | 67,041,000 | 128,412,000 | 55,450,000 | 72,962,000 | 60,159,000 |
| Dec 2022 | 5,091,000 | -85,757,000 | -62,809,000 | 87,810,000 | 84,577,000 | 3,233,000 | -79,883,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$20,344,000
NetIncome TTM
$-24,517,000
OpCashFlow TTM
—
Assets (Latest)
$77,626,000
Forward EPS
$-2.31
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $4.22 · call volume: 199 · put volume: 20
Expected Move to 2026-12-18:
±$1.75
(41.47%) —
implied range
$2.47 –
$5.97
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MTNB | Matinas BioPharma Holdings, Inc. | $41.58M | $2.83 | — |
| NSRX | Nasus Pharma Ltd | $42.52M | $3.63 | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $41.30M | $0.96 | — |
| VERU | VERU INC. | $41.26M | $2.42 | — |
| GRCE | Grace Therapeutics, Inc. | $42.91M | $2.04 | — |
News headlines (Yahoo Finance, 1h cache)
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2026-10-06 11:30 · Yahoo
Scynexis stock surges on $214M BARDA contract for SCY-247
2026-09-28 13:58 · Yahoo
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
2026-09-28 12:10 · Yahoo
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
2026-09-28 11:30 · Yahoo
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
2026-09-22 12:00 · Yahoo
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
2026-09-15 12:00 · Yahoo
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
2026-09-10 12:00 · Yahoo
SCYNEXIS to Participate in Upcoming Investor Conferences
2026-09-01 12:30 · Yahoo
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-10 20:30 · Yahoo
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2026-06-30 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.